Enanta Pharmaceuticals (ENTA) Operating Expenses (2012 - 2026)

Enanta Pharmaceuticals' Operating Expenses history runs 15 years deep, the most recent figure standing at $29.0 million for Q1 2026.

• Quarterly Operating Expenses fell 26.47% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.6 million (down 22.2% YoY) and the FY2025 annual result came in at $150.7 million, down 20.42% from the prior year.
• Operating Expenses was $29.0 million for Q1 2026 at Enanta Pharmaceuticals, down from $29.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $57.2 million in Q1 2023 and bottomed at $29.0 million in Q1 2026.
• A 5-year average of $45.1 million and a median of $47.4 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses increased 8.91% — and 2026, when it decreased 26.47%.
• Enanta Pharmaceuticals' Operating Expenses stood at $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then slipped by 23.42% to $40.5 million in 2024, then fell by 26.26% to $29.9 million in 2025, then retreated by 2.87% to $29.0 million in 2026.
• Business Quant data shows ENTA's Operating Expenses at $29.0 million in Q1 2026, $29.9 million in Q4 2025, and $33.5 million in Q3 2025.